U.S. markets open in 5 hours 41 minutes

Legend Biotech Corporation (LEGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
59.83-0.27 (-0.45%)
At close: 04:00PM EST
60.24 +0.41 (+0.69%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close60.10
Bid0.00 x 1100
Ask0.00 x 800
Day's Range59.00 - 60.50
52 Week Range42.90 - 77.32
Avg. Volume1,023,964
Market Cap10.906B
Beta (5Y Monthly)-0.02
PE Ratio (TTM)N/A
EPS (TTM)-2.96
Earnings DateMar 11, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est86.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for LEGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Legend Biotech Corporation
    NARI: Rating increased to a HOLDINARI MEDICAL INC has an Investment Rating of HOLD; a target price of $47.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • Business Wire

    Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results

    SOMERSET, N.J., February 13, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, will host a conference call for investors at 8:00 am ET on Monday, March 11, 2024, to review fourth-quarter and full-year 2023 results.


    Matthews Emerging Markets Small Companies Fund Bolsters Position in CarTrade Tech Ltd

    Insightful 13F Filing Update Reveals Strategic Portfolio Adjustments

  • Reuters

    UPDATE 6-US FDA seeks 'boxed warning' for CAR-T cancer therapies

    The U.S. health regulator on Monday asked a host of drugmakers, including Gilead Sciences, Johnson & Johnson and Novartis, to add a serious warning on the label of their cancer therapies that use CAR-T technology. The other cancer therapies include Bristol Myers Squibb's Breyanzi and its partnered therapy, Abecma, with 2seventy bio, J&J unit Janssen and Legend Biotech's Carvykti, Novartis AG's Kymriah, and Gilead unit Kite's Tecartus and Yescarta. CAR-T treatment generally involves extracting disease-fighting white blood cells known as T-cells from a patient, re-engineering them to attack cancer and infusing them back into the body.